Cyclophosphamide
HR Positive/HER-2 Negative Breast Cancer
George Washington UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the HR Positive/HER-2 Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eftilagimod Alfa George Washington University | Phase 2 | CCC |
Docetaxel George Washington University | Phase 2 | CCC |
Inno-206 George Washington University | Phase 2 | CCC |
cgt6297 Cogent Biosciences, Inc. | Phase 1 | CC |
ntq1062 Nanjing Chia-tai Tianqing Pharmaceutical | Phase 1 | CC |
FULVESTRANT Nanjing Chia-tai Tianqing Pharmaceutical | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →